Drugs Flashcards
Bleomycin (Blenozane)
Classification: antitumor antibiotic
Indication: HD, HNL, sq cell HN, melanoma, sq of skin, cervix, vulva, testicular
Route: IV, SC, IM
Side Effects: pulmonary toxicity, renal toxicity
Doxorubicin (Adriamycin or Rubex)
Classification: antitumor antibiotic, anthracyclines
Indication: breast, liver, lung, ovarian, prostate; NHL, HD, MM, ALL, AML; sq HN
Side Effects: myelosuppression, N/V, mucositis, diarrhea, anorexia
Doxorubicin liposomal (Doxil)
Classification: antitumor antibiotic, anthracyclines
Indication: AIDS-related Kaposi’s Sarcoma, ovarian, MM, sarcoma, Heptocellular CA
Side Effects: myelosuppression, N/V, mucositis, diarrhea
Etoposide (VePesid or VP-16)
Classification: Epipodophyllotoxins
Indication: small & nonsmall lung CA, HD, NHL, gastric CA, germ cell tumors (testicular)
Side Effects: myelosuppression, N/V, mucositis, diarrhea, metallic taste
Vincristine (Oncovin)
Classification: Vinca alkaloids
Indication: ALL, AML, CML, D, NHL, MM, sm cell lung CA, rhabdomyosarcoma, neuroblastoma, Ewing’s sarcoma, Wilms’ tumor, brain and thyroid CA
Side Effects: myelosuppression, sensory neuropathy, constipation, jaw pain
Interactions: decrease drug activity - St. John’s Wort, phenobarbital dexamethasone; increase drug activity - grapefruit, ketoconazole, erythromycin
*Omega-3’s may enhance clinical benefit of Vincristine
Vinblastine (Velban)
Classification: Vinca Alkaloids
Indication: Breast, testicular, HD, sq cell NH, sarcoma
Side Effects: myelosuppression, mucositis, stomatitis, constipation, jaw pain, HTN
Interactions: decrease drug activity - St. John’s Wort, phenobarbital dexamethasone; increase drug activity - grapefruit, ketoconazole, erythromycin
Vinorelbine (Navelbine)
Classification: Vinca alkaloids
Indication: Breast, ovarian, non-sm cell lung CA
Side Effects: Myelosuppression, N/V, stomatitis, constipation, anorexia, elevated liver function tests
Rituximab (Rituxan)
Classification: monoclonal antibody CD20
Indication: B-cell NHL, CLL
Side Effects: infusion reaction, myelosuppression, tumor lysis syndrome, skin reactions, mild N/V
Pertuzumab (Perjeta)
Classification: monoclonal antibody Her2/neu
Indication: metastatic breast CA
Side Effects: infusion reaction, myelosuppression, asthenia, infections, mild N/V, cough, dyspnea, sinusitus
Trastuzumab (Herceptin)
Classification: monoclonal antibody Her2/neu
Indication: metastatic breast CA, metastatic gastric CA
Side Effects: infusion reaction, myelosuppression (rare), cardio-toxicity, N/V, mild D, pulmonary toxicity
Panitumumab (Vectibix)
Classification: monoclonal antibody EGFR
Indication: colorectal CA
Side Effects: infusion reaction, acneiform skin rash, pruritis, pulmonary toxicity, hypomagnesemia, Diarrhea, malaise
Interactions/concerns: hypomagnesemia – monitor Mg closely, particularly with elderly or pts with low baseline Mg
Cetuximab (Erbitux)
Classification: monoclonal antibody EGFR
Indication: colorectal CA, NH
Side Effects: infusion reaction, acneiform skin rash, pruritis, pulmonary toxicity, hypomagnesemia, Diarrhea, malaise, N/V, anorexia
Interactions/concerns: hypomagnesemia – monitor Mg closely, particularly with elderly or pts with low baseline Mg and received Oxalipatin (Eloxatin)
Megesterol acetate (Megace)
Classification: progesterone
Indication: breast, endrometrial, renal cell. Also appetite stimulant in CA and AIDS
Route: PO
Side Effects: weight gain (fluid retention), thromboembolic events, N/V, menstral bleeding, hot flashes, sweating, mood change, hyperglycemia
Carboplatin (Paraplatin)
Classification: alkylating agent
Indication: bladder, endometrial, germ cell, HN, lung, ovarian
Side Effects: myelosuppression, N/V!, renal toxicity, hypersensitivity reaction, alopecia, peripheral neuropathy
Cisplatin (Platinol or CDDP)
Classification: alkylating agent
Indication: bladder, cervical, esophageal, HN, lung, NHL, ovarian, prostate, testicular
Side Effects: Acute and delayed N/V, metallic state, myelosuppression, peripheral neuropathy, SIADH, renal toxicity, hypomagnesmia, ototoxicity, infusion reaction
Rigorous hydration is needed to prevent nephrotoxicity (PO and IVF). Monitor renal function/lytes. At risk include elderly, low Mg pts, impaired renal function at baseline
Interactions: Omega-3’s may enhance clinical benefits of Cisplatin; Curcumin - may sensitize cisplatin-resistant cells to cisplatin, improving efficacy. May reduce cisplatin-induced neurotoxicity. Safe to add into diet.
Cyclophosphamide (Cytoxan, CTX)
Classification: alkylating agent
Indication: breast, ovarian, MM, NHL, HD, CLL, Mycosis fungoides, neuroblastoma, sarcoma, Wilm’s tumors
Route: PO, IP, IV. When taken oral - take early in the day with vigorous hydration (3L) throughout the day.
Side Effects: Myelosuppression, N/V, bladder and cardiac toxicity, SIAD, Alopecia
Interaction: may increase effects of anti-coagulation so anticoag meds may need to be reduced
Dacarbazine (DTIC)
Classification: alkylating agent
Indication: HD, MM, neuroblastoma, sarcoma
Side Effects: myelosuppression, N/V (up to 12 hrs), flu-like symptoms, CNS toxicity, photo-sensitivity
Oxaliplatin (Eloxatin)
Classification: alkylating agent
Indication: colorectal, pancreatic, gastroesophageal
Side Effects: Myelosuppression, N/V/D, neurotoxicity, hepatic toxicity, allergic reaction
Interactions: Minimize cold exposure, up to 5 days post-infusion (avoid eating/drinking cold/frozen foods). Use care when handling cold/frozen items. Vit B6 (50-100 mg BID/TID) may help prevent/reduce hand-food syndrome
Fludarabine (Fludara)
Classification: anitmetabolics
Indication: CLL, NHL, T-cell Lymphoma, hairy cell leukemia
Side Effects: Myelosuppression, N/V, D, neuro-toxicity, rash
Flurouracil (5-FU)
Classification: anitmetabolics
Indication: breast, colorectal, GI, HN, pancreatic, ovarian, hepatoma
Route: IV - have pt melt ice chips in mouth 10-15 min pre/post IV bolus infusion to reduce incidence of mucositis
Side Effects: myelosuppression, N/V, D, mucositis, hand-foot syndrome, cardiac toxicity, photo-sensitivity
Interactions: Vit B6 (50-100 mg BID/TID) may help prevent/reduce hand-food syndrome
Gemcitabine (Gemzar)
Classification: anitmetabolics
Indication: pancreatic, breast, ovarian, NSCLC
Side Effects: myelosuppression, N/V, pulmonary toxicity, rash, flu-like symptoms
Methotrexate (Folex, Rheumetrex)
Classification: anitmetabolics
Indication: bladder, breast, H&N, NHL, CNS lymphoma, ALL, sarcoma
Route: IM, IV, IT, PO - Oral: take on empty stomach 1 hr before, 2 hr after meals. Avoid folic acid and derivatives. Avoid alcohol (may increase hepatic toxicity)
Side Effects: myelosuppression, N, mucositis, oral/GI ulcerations, renal toxicity, hepatic toxicity, photo-sensitivity
Interactions: high doses must be followed by Leucovorin and hydration
Pemetrexed (Alimta)
Classification: anitmetabolics
Indication: mesothelioma
Side Effects: myelosuppression, N/V, D, fatigue, rash
Interactions: Often given with cisplatin.
To prevent severe anemia, take dietary supplement prior and during treatment - folic acid (350-1000 ug PO) 1 week prior to treatment, daily and post treatment; B12 (1000ug) IM given every 3 cycles, beginning at first week prior to treatment
Paclitaxel (Taxol)
Classification: Taxens
Indication: bladder, breast, esophageal, H and N, ovarian, pancreatic, prostate, sm cell Lung, NSCLC
Side Effects: myelosuppression, Diarrhea, Mucositis, sensory neuropathy, hypersensitivity reaction, alopecia
Interactions: drink at least 2-3 quarts every 24 hours; omega-3’s may reduce toxicity
Docetaxel (Taxotere)
Classification: Taxens
Indication: breast, gastric, H and N, ovarian, prostate, NSCLC
Side Effects: myelosuppression, nucositis, diarrhea, neurotoxicity, fluid retention, skin/nail changes
Paclitaxel Protein-bound (Abraxane)
Classification: Taxens
Indication: Breast, NSCLC
Side Effects: myelosuppression, N/V, Diarrhea, Mucositis, arthralgia, myalgia, sensory neuropathy, alopecia